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Abstract
The IgG4 subclass of antibodies exhibits unique characteristics that suggest it may function in an 
immunoregulatory capacity. The inhibitory function of IgG4 has been well documented in allergic 
disease by the demonstration of IgG4 blocking antibodies, but similar functions have not been 
explored in autoimmune disease. Bullous pemphigoid (BP) is a subepidermal autoimmune 
blistering disease characterized by autoantibodies directed against BP180 and an inflammatory 
infiltrate including eosinophils and neutrophils. Animal models have revealed that the NC16A 
region within BP180 harbors the critical epitopes necessary for autoantibody mediated disease 
induction. BP180 NC16A-specific IgG belong to the IgG1, IgG3, and IgG4 subclasses. The 
purpose of this study was to determine effector functions of different IgG subclasses of NC16A-
specific autoantibodies in BP. We find that IgG4 anti-NC16A autoantibodies inhibit the binding of 
IgG1 and IgG3 autoantibodies to the NC16A region. Moreover, IgG4 anti-NC16A blocks IgG1 
and IgG3 induced complement fixation, neutrophil infiltration, and blister formation clinically and 
histologically in a dose-dependent manner following passive transfer to humanized BP180-NC16A 
mice. These findings highlight the inhibitory role of IgG4 in autoimmune disease and have 
important implications for the treatment of BP as well as other antibody mediated inflammatory 
and autoimmune diseases.
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1. INTRODUCTION
IgG4 is unique among IgG subclasses as it lacks the ability to fix complement and does not 
effectively bind Fcγ receptors II or III [1–3]. Additionally, due to specific amino acid 
differences in the Fc region, IgG4 is also able to participate in half molecule (or Fab arm) 
exchange, which results in asymmetric and functionally monovalent antibodies [4–6]. These 
features have led to the premise that IgG4 acts in an immunoregulatory role. Indeed, while 
IgG4 is present in relatively low amounts in the sera of healthy individuals, IgG4 levels 
increase upon repeat antigen exposure [7]. In fact, increases in IgG4 levels can be used as a 
marker of successful immunotherapy in patients with allergies, where IgG4 antibodies are 
felt to dampen the IgE response by acting as blocking antibodies [8–10].
Despite the accumulating evidence that IgG4 functions in a regulatory capacity, there are 
many diseases in which IgG4 is pathogenic. It is well accepted that the pathogenic 
autoantibodies in the intraepidermal blistering diseases pemphigus vulgaris and pemphigus 
foliaceus are predominantly of the IgG4 subclass [11, 12]. IgG4 antibodies have also been 
reported to play a role in the pathogenesis of membranous glomerulonephritis and 
thrombotic thrombocytopenic purpura [13–15]. In addition, diseases in which IgG4 plasma 
cells are involved are becoming more frequently recognized and reported [16–18]. These 
diseases, collectively termed IgG4-related diseases, can manifest in multiple organ systems 
exhibiting a wide range of clinical presentations, but are generally characterized by 
fibroinflammatory changes, IgG4 plasma cell infiltrate, and mild tissue eosinophilia with 
variable elevation in serum IgG4 levels [19, 20]. Whereas in pemphigus, the IgG4 anti-
desmoglein 1 and 3 autoantibodies are directly pathogenic to the epidermis, impairing the 
cell adhesion mechanism without the intervention of complement or inflammatory cells [11, 
12], the exact role of IgG4 antibodies in other IgG4 mediated and IgG4-related diseases is 
not well understood. Moreover, while the inhibitory capacity of IgG4 has been well 
demonstrated in the setting of allergy, the potential regulatory role of IgG4 antibodies in 
inflammatory and antibody mediated autoimmune diseases had not been investigated.
Bullous pemphigoid (BP) is an autoantibody mediated autoimmune blistering disease of the 
skin characterized clinically by tense bullae formation and histologically by subepidermal 
clefting and dermal infiltration of eosinophils and neutrophils [21]. Direct 
immunofluorescence studies show IgG and complement deposition along the dermal 
epidermal junction [22, 23]. The disease is caused by autoantibodies directed against BP180 
(also termed type XVII collagen), a transmembrane glycoprotein that is located in the 
hemidesmosome and critical for adhesion of the basal keratinocytes to the dermis [24–26]. 
Previous studies have shown that the noncollagenous 16A (NC16A) region of the BP180 
ectodomain contains the major epitopes recognized by autoantibodies from BP sera [27, 28]. 
As the NC16A domain is poorly conserved between humans and mice, the development of 
the humanized NC16A mice containing the human NC16A domain has allowed for a more 
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precise understanding of how autoantibodies from BP patients induce disease [29, 30]. 
Passive transfer of BP IgG is pathogenic in NC16A mice, but not wildtype mice, confirming 
the importance of the NC16A domain in pathogenicity of disease [30, 31].
IgG anti-NC16A autoantibodies are predominantly of the IgG1 and IgG4 subclasses [32, 
33]. While many aspects of BP immunopathology are well understood, the role of different 
IgG subclasses remains unclear. The aim of this study was to determine the role of IgG anti-
NC16A subclasses in the pathogenesis of BP using the humanized NC16A mouse model. 
We show that IgG4 anti-NC16A autoantibodies inhibit the binding of anti-NC16A IgG1,3 to 
the cutaneous basement membrane zone (BMZ), block complement fixation and neutrophil 
infiltration, and prevent blister formation, clinically and histologically, in a dose dependent 
manner following passive transfer to NC16A mice. These findings have important 
implications for the treatment of BP as well as other antibody mediated inflammatory and 
autoimmune diseases as well.
2. MATERIALS AND METHODS
2.1 Patients, sera, and antibody purification
Serum samples were collected from three patients with active BP (BP1, BP2, and BP3). 
NC16A-specific total IgG were purified from BP patient sera using a protein G column, 
followed by an NC16A-specific glutathione sepharose column as described [30]. NC16A-
specific IgG1,3 and 4 were purified from NC16A-specific total IgG using human IgG4-
specific columns (Amersham Biosciences). The concentration and purity of NC16A-specific 
IgG4 (eluate) and NC16A-specific IgG1 and 3 (flow through) were determined by human 
IgG subclass-specific ELISA (Southern Biotechology). The purity of NC16A-specific 
IgG1,3 and IgG4 were 95% and 98%, respectively. Purified IgG and IgG subclass fractions 
were concentrated by ultrafiltration (Millipore) and used for in vitro and in vivo 
experiments.
2.2 In vitro inhibition of IgG binding and C′ activation at the basement membrane zone
Anti-NC16A IgG1,3 (1 μg/ml) were incubated with normal human IgG4 or NC16A-specific 
IgG4 (0.25 μg/ml) and then incubated with skin sections of NC16A mice. Binding of anti-
NC16A IgG1 and 3 to the BMZ was detected by FITC-conjugated anti-human IgG1 and 
IgG3. For the in vitro C′ fixation assay, anti-NC16A IgG1,3 were incubated with normal 
human IgG4 or NC16A-specific IgG4 and then incubated with skin sections of NC16A mice 
in the presence of freshly prepared human serum or commercial rabbit serum as a 
complement source. The complement C3 deposition at the BMZ was detected by FITC-
conjugated anti-human or anti-rabbit C3 (Cappel Laboratories).
2.3 In vitro complement fixation assay
Antibody-sensitized sheep erythrocytes (EA), human serum complement, and GVB++ buffer 
were purchased from Complement Technology (Tyler, TX). The ability of NC16A-specific 
IgG1,3 and IgG4 to fix complement was determined by following the protocol by the 
company and as described [34, 35] with some modifications. Briefly, EA (1×108 cells/ml), 
complement (1:400 dilution), and NC16A-specific IgG (100 μg/ml) were incubated in the 
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presence of GST-NC16A fusion protein (0–100 μg/ml) at 37°C for 1 h. After centrifugation, 
the absorbance of the supernatant was determined at 540 nm by a microtiter plate reader. 
The complement fixation activity was expressed as percent of sheep erythrocyte lysis 
inhibition.
2.4 Flow cytometry
Mouse neutrophils were isolated as described [36]. 1×106 neutrophils were incubated with 
anti-NC16A IgG (0–10 μg/ml) and goat anti-human IgG-FITC conjugate. FITC positive 
cells were quantified by flow cytrometry.
2.5 Mice and antibody passive transfer
The humanized NC16A mice were generated as described [30]. A 50 μl aliquot of sterile 
IgG (control human IgG or affinity-purified NC16A-specific IgG) in PBS was administered 
to neonatal mice by intradermal or intraperitoneal injection [30]. The mouse skin was 
examined 24 h after injection. The extent of cutaneous disease (clinical disease activity) was 
scored as follows: “(−)”, no detectable skin disease; “1+”, mild erythematous reaction with 
no evidence of the “epidermal detachment” sign; “2+”, intense erythema and “epidermal 
detachment” sign involving 10–50% of the epidermis in localized areas; and “3+”, intense 
erythema with frank “epidermal detachment” sign involving more than 50% of the 
epidermis. After clinical examination, the animals were sacrificed, and skin and serum 
specimens were obtained. The skin sections were used for routine histological examination 
by light microscopy (H/E staining) to localize the lesional site and neutrophil infiltration. 
Direct immunofluorescence assays were done to detect deposition of human IgG and mouse 
C3 at the basement membrane zone using commercially available FITC-conjugated goat 
anti-human and monospecific goat anti-mouse C3 IgG (Cappel Laboratories). 
Myeloperoxidase (MPO) enzymatic assay was performed to quantify the neutrophil 
accumulation at the skin injection site as described below.
2.6 In vivo inhibition of NC16A-specific IgG1,3-induced BP
Neonatal NC16A mice were injected intradermally with anti-NC16A IgG1,3 in the presence 
of normal human IgG4 control or different ratios of anti-NC16A IgG4. The mice were 
examined clinically for disease activity 24 hours post injection.
2.7 Quantification of infiltrating neutrophils
Infiltrating neutrophils in the antibody-injected skin were quantified by measuring tissue 
MPO activity as described [30, 37, 38] using purified MPO as standard. MPO content was 
expressed as relative MPO activity (OD460nm reading/mg protein of the mouse skin injected 
with pathogenic anti-mBP180 IgG minus OD460nm reading/mg protein of the mouse skin 
injected with control IgG). Protein concentrations were determined by the Bio-Rad dye-
binding assay using BSA as a standard.
2.8 Quantification of C5a levels
Skin from the IgG injection site of the diseased and control mice was homogenized in PBS 
to extract proteins. The level of mouse C5a (mC5a) in the skin was measured by ELISA 
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(R&D Systems, Minneapolis, MN) [39]. Microtiter plates were coated with a rat anti-mouse 
C5a antibody, incubated with skin protein extracts, followed by goat anti-mC5a detection 
antibody, and then developed and read at OD492nm. The C5a level was expressed as OD492 
reading/mg protein.
2.9 Statistics
The data are expressed as mean ± SEM and were analyzed using the Student’s t-test. A p 
value less than 0.05 is considered significant.
2.10 Study approval
Animal care and animal experiments were in accordance with the Animal Care Committee 
at the University of North Carolina-Chapel Hill. Written informed consent was received 
from participants prior to inclusion in the study.
3. RESULTS
3.1 IgG1, IgG3, and IgG4 are the dominant IgG subclasses among NC16A-specific 
autoantibodies
To determine the concentration of IgG subclasses among NC16A-specific autoantibodies, 
anti-NC16A specific total IgG was purified from the sera of three BP patients by NC16A 
affinity purification. Levels of anti-NC16A IgG1, IgG2, IgG3, and IgG4 were determined by 
quantitative human subclass ELISA on the purified NC16A specific fraction. As shown in 
Figure 1, IgG1 is the dominant IgG subclass among NC16A-specific autoantibodies ranging 
from 0.55–1.41 mg/ml serum. Lower levels of IgG3 and IgG4 anti-NC16A autoantibodies 
are detected in all three patients as well. IgG2 is detected at very low levels in BP1 and is 
below the level of detection in BP2 and BP3.
3.2 IgG anti-NC16A induced clinical blistering in NC16A mice is dose dependent
Our group has previously shown that IgG anti-NC16A autoantibodies are pathogenic upon 
passive transfer to NC16A mice [30]. In an effort to determine the optimal dose necessary to 
induce blister formation, we conducted a dose titration study using anti-NC16A total IgG 
derived from each of three BP sera (BP1, BP2, and BP3). Neonatal NC16A mice were 
injected with different amounts of purified anti-NC16A total IgG ranging from 100 to 300 
ug/g of body weight. The mice were examined for clinical signs of disease at 24 hours post 
injection. Mice injected with 300 (Figure 2A, panels a, b) and 200 (Figure 2A, panels c, d) 
but not 100 ug/g of body weight (Figure 2A, panels e, f) anti-NC16A IgG develop clinical 
and histological subepidermal blisters. Anti-NC16A IgG induces clinical blistering in a 
dose-dependent fashion as shown in Figure 2B with optimal dosing of 300 ug anti-NC16A 
IgG/g body weight for BP1 and 3 and 200 ug anti-NC16A IgG/g body weight for BP2. 
Optimal dosing is defined as the dose necessary to reach a clinical disease score of 
approximately 2.5.
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3.3 IgG4 anti-NC16A inhibits binding and complement fixation of anti-NC16A IgG1,3 at the 
basement membrane zone in vitro
While previous studies have shown that anti-NC16A total IgG can bind the basement 
membrane zone (BMZ) and fix complement on NC16A murine skin in vitro [30], we wanted 
to investigate possible differences between the anti-NC16A subclasses in terms of BMZ 
binding and complement fixation. IgG4 anti-NC16A autoantibodies were purified from anti-
NC16A total IgG using a human IgG4 affinity column, resulting in an anti-NC16A IgG1,3 
flow through fraction and an anti-NC16A IgG4 eluate fraction. Skin sections of NC16A 
mice were incubated with anti-NC16A IgG1,3, IgG4, or both IgG1,3 and IgG4. As shown in 
Figure 3A, IgG1,3 and IgG4 are both independently able to bind the BMZ in NC16A murine 
skin (Figure 3A, panels a and b). Pre- or co-incubation of IgG4 anti-NC16A, but not control 
IgG4 reduces binding of anti-NC16A IgG1,3 at the BMZ as detected by FITC-conjugated 
IgG1 specific secondary antibody (Figure 3A, panels c and d) or FITC-conjugated IgG3 
specific secondary antibody (data not shown).
Anti-NC16A IgG1,3 is able to fix complement as determined by C3 deposition at the BMZ, 
while IgG4 anti-NC16A is not (Figure 3B, panels a and b). Pre- or co-incubation of IgG4 
anti-NC16A, but not control IgG4 significantly inhibits complement fixation by anti-NC16A 
IgG1,3 (Figure 3B, panels c and d).
3.4 IgG4 anti-NC16A inhibits anti-NC16A IgG1,3 induced BP in vivo in a dose dependent 
manner
Knowing that IgG4 anti-NC16A inhibits binding and C′ fixation of anti-NC16A IgG1,3 in 
vitro, we then tested whether anti-NC16A IgG4 were inhibitory in vivo. Neonatal NC16A 
mice were injected intradermally with BP1-derived anti-NC16A IgG1,3 (300ug/g body 
weight) in the presence of control IgG4 or BP1-derived anti-NC16A IgG4 at a ratio of 
10:2.5 (anti-NC16A IgG1,3:IgG4). The neonates were examined 24 hours post injection. As 
shown in Figure 4A anti-NC16A IgG1,3 binds to the BMZ (Figure 4A, panel b and c), fixes 
complement (Figure 4A, panel d), and induces clinical and histologic blistering in vivo 
(Figure 4A, panels a and e) in the presence of control IgG4. In contrast, the presence of anti-
NC16A IgG4 inhibits IgG1 binding (Figure 4A, panel h) and complement fixation (Figure 
4A, panel i) and blocks clinical and histologic blister formation in vivo (Figure 4A, panels f 
and j) although mouse skin showed IgG (due to IgG4) deposition at the BMZ (Figure 4A, 
panel g).
Using different ratios of BP1-derived anti-NC16A IgG1,3 to IgG4 (10:0 – 10:5), we further 
demonstrated that anti-NC16A IgG4 inhibits anti-NC16A IgG1,3-induced C′ activation (as 
measured by levels of C5a in the skin), neutrophil infiltration (as measured by skin MPO 
activity) and clinical disease severity (clinical disease score) in a dose dependent fashion 
(Figure 4B).
3.5 Anti-NC16A IgG4 inhibits anti-NC16A IgG1,3 induced BP from multiple BP sera in vivo
Although BP1 derived anti-NC16A IgG4 was able to block BP1-derived anti-NC16A IgG1,3 
induced BP in vivo, we wanted to determine if anti-NC16A IgG4 could block anti-NC16A 
IgG1,3 induced BP using anti-NC16A IgG1,3 derived from multiple BP sera. Neonatal 
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NC16A mice were injected intradermally with anti-NC16A IgG1,3 (300ug/g body weight) 
from BP1, BP2, and BP3 in the presence of control IgG4 or anti-NC16A IgG4 from BP1 at a 
ratio of 10:5 and examined at 24 hours post injection. The presence of BP1 anti-NC16A 
IgG4 inhibits clinical blister formation (Figure 5A and 5B), complement fixation and 
activation (Figure 5C and 5D), and neutrophil infiltration (Figure 5E) induced by anti-
NC16A IgG1,3 from BP1, BP2, and BP3.
3.6 Anti-NC16A IgG4 bind to Fcγ receptors and induce BP in C5a reconstituted NC16A 
mice
Anti-NC16A IgG4 inhibit complement fixation activity of anti-NC16A IgG1,3 in the skin 
tissue assay (Figure 3) and anti-NC16A IgG1,3-mediated complement fixation in vivo 
(Figures 4, 5). This inhibition activity is most likely due to competition for IgG binding 
(occupying) site(s) on the NC16A domain between anti-NC16A IgG1,3 and IgG4. To further 
explore this possibility, we determined whether anti-NC16A IgG4 are capable of blocking 
anti-NC16A IgG1,3 complement fixing activity in vitro using a liquid phase sheep red blood 
cell lysis assay. As expected, immune complexes of NC16A and NC16A IgG1,3 but not 
IgG4 fix complement (Figure 6A). Further, when mixing NC16A, anti-NC16A IgG1,3 and 
IgG4 together, the complement fixation activity of anti-NC16A IgG1,3 was drastically 
reduced in a IgG4 dose dependent fashion (Figure 6B). In experimental BP, binding of anti-
BP180 IgG Fc to IgG FcγRs (especially FcγRIII) is required for activating infiltrating 
neutrophils to release tissue injury proteolytic enzymes [40]. To rule out the possibility that 
anti-NC16A IgG1,3 and IgG4 are different in their ability to bind FcγRs, we incubated anti-
NC16A IgG1,3 and IgG4 with purified mouse neutrophils and compared their FcγR binding 
by flow cytometry. Anti-NC16A IgG1,3 and IgG4 at 1, 2.5 and 10 μg/ml concentrations 
show comparable binding to neutrophil FcγRs (Figure 7A, 7B).
The finding that anti-NC16A IgG4 lack complement fixing activity, but are capable of 
binding to FcγRs lead us to speculate that non-pathogenic anti-NC16A IgG4 should induce 
BP in mice when C5a is provided locally. As shown in Figure 7, NC16A mice were injected 
locally with anti-NC16A IgG4 plus mC5a or BSA control. Both groups of mice show IgG4, 
but not C3 deposition at the BMZ by direct IF; however, only mice reconstituted with mC5a 
developed typical BP skin lesions (Figure 7C). Clinical disease activity (Figure 7D) and 
neutrophil infiltration (Figure 7E) in the diseased mice were mC5a dose-dependent. Thus, 
once neutrophils are recruited by exogenous mC5a, IgG4 anti-NC16A antibodies are able to 
activate neutrophils via FcR binding initiating the disease cascade.
4. DISCUSSION
IgG4 and its contribution to the pathogenesis of disease have gained significant attention 
over the past several years across a number of fields including inflammatory disease, allergy, 
and autoimmunity. The unique properties of IgG4 suggest that it may function to regulate 
immune responses mediated by other IgG subclasses. While the inhibitory capacity of IgG4 
has been well demonstrated in the field of allergy, the potential regulatory role of IgG4 in 
inflammatory and antibody mediated autoimmune diseases had not been investigated. Using 
BP as a model of autoantibody mediated autoimmune disease, we clearly demonstrate that 
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IgG4 can function in an inhibitory capacity in autoantibody mediated autoimmune disease. 
To our knowledge, this study is the first to show inhibition as a major effector function of 
IgG4 in autoimmunity.
BP provides an excellent model for exploring the inhibitory role of IgG4 in autoantibody 
mediated autoimmune disease. Studies using animal models of BP have demonstrated that 
the pathogenic mechanisms of autoantibody mediated blister formation in BP are complex 
and involve a multi-step process that includes autoantibody binding, complement fixation 
and activation, inflammatory cell infiltration, BMZ degradation, and ultimately 
subepidermal clefting that results in clinical disease. Earlier studies using total IgG from BP 
patients have shown that IgG mediated blister formation is complement dependent. 
Subsequent studies using monoclonal antibodies have raised the possibility that some 
autoantibodies are capable of inducing blister formation in the absence of complement [41, 
42]. A recent report describes two cases of BP with dominant IgG4 and without C3 
deposition at the BMZ, indicating that blister formation could be complement-independent 
in some BP cases [43]. However, it is well documented that the majority of human BP skin 
(>90%) have complement (C3 deposition), and less than 10% of BP patients are C3-negative 
at the basement membrane zone by direct IF [44, 45]. Here, we show using highly purified 
IgG subclass fractions derived from BP patients with more classic or typical BP that NC16A 
specific IgG1,3 are able to bind the BMZ, fix and activate complement, and induce blister 
formation in vivo. While anti-NC16A IgG4 is able to bind the BMZ, it is unable to fix 
complement and does not induce blister formation. Furthermore, co- or pre-incubation of 
IgG1,3 with IgG4 inhibits complement fixation, activation, neutrophil infiltration and blister 
formation.
There are several possible mechanisms by which IgG4 anti-NC16A antibodies inhibit BP. 
The most obvious explanation is that IgG4 anti-NC16A binds NC16A, thereby blocking 
IgG1,3 NC16A specific antibodies from binding the same region. This mechanism is 
strongly supported by our studies as the pre- or co-incubation of IgG4 anti-NC16A blocks 
IgG1,3 anti-NC16A binding in vitro and in vivo by immunofluorescence (Figure 3A panel d 
and Figure 4A panel h).
However, the more fundamental and underlying question is why IgG4 anti-NC16A 
antibodies bind the pathogenic NC16A domain, but do not induce disease. It is known that 
IgG4 lacks the ability to fix complement [2, 3] and our current studies corroborate that this 
finding extends to IgG4 anti-NC16A antibodies. Another function of IgG4 that may play a 
role in BP pathogenesis or lack thereof is the ability of IgG4 to bind FcγRs. While older 
studies have suggested that IgG4 is not able to bind FcγRs, more recent studies suggest that 
human IgG4 indeed bind FcγRs [1–3, 46]. In this study we demonstrate that IgG1,3 and 
IgG4 anti-NC16A antibodies show comparable binding to neutrophil FcγRs (Figure 7A, 
7B). These features may explain why IgG4 anti-NC16A antibodies are not directly 
pathogenic as both complement activation for recruiting neutrophils and FcR binding for 
activating infiltrating neutrophils are pivitol in experimental BP [30, 39, 40]. Supporting this 
theory, IgG4 anti-NC16A IgG4 induce BP in mice when C5a is provided locally to induce 
neutrophil infiltration (Figure 7C). Clinical disease activity (Figure 7D) and neutrophil 
infiltration (Figure 7E) in the diseased mice were mC5a dose-dependent. Taken together, 
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these results clearly demonstrate that anti-NC16A IgG4 bind to NC16A domain and block or 
reduce pathogenic anti-NC16A IgG1,3 binding to the same or nearby sites. This blockade 
results in reduced anti-NC16A IgG1,3-mediated complement activation and subsequent 
neutrophil infiltration and BP blistering.
While this study did not set out to address the requirement of complement in the 
pathophysiology of BP, the results suggest that complement is a critical part of the 
pathogenesis of blister formation. There are many factors that may account for the 
seemingly disparate findings between this and studies from other groups. First of all, 
differences in autoantibody source and composition may have a significant impact on both 
complement and pathogenesis studies. The clinical relevance of our results are strengthened 
by the use of highly purified, yet oligoclonal anti-NC16A IgG1,3 and IgG4 fractions, which 
are specific to the critical NC16A domain, but still inclusive of anti-NC16A autoantibodies 
to multiple epitopes within the NC16A region. This approach eliminates the possible 
misinterpretation of results that can occur when using monoclonal antibodies against a 
single epitope on NC16A, which may not be fully representative of the true oligoclonal anti-
NC16A response. It is possible that patient sera have varying ratios of IgG1,3:IgG4. When 
total IgG is used, it is conceivable that some sera would be predominantly IgG1,3 and 
therefore able to fix complement and induce blisters, whereas other sera would have more 
significant levels of IgG4 that would block complement fixation and blister formation. For 
example, anti-NC16A IgG4 inhibition of anti-NC16A IgG1,3 induced disease is most 
significant when it is present at ratios of 10:5 or 10:2.5 (anti-NC16A IgG1,3:IgG4). As 
determined in Figure 1, the naturally occurring ratio of anti-NC16A IgG1:IgG4 in BP 
patient sera is approximately 10:1. At this ratio, the inhibitory capacity of anti-NC16A IgG4 
is less remarkable (see Figure 4B). Secondly, differences in autoantibody dosing may 
influence results. In this study, dose finding studies were performed to avoid possible 
confounding results that can be seen with supraphysiologic dosing that may not be relevant 
clinically. Finally, another possible explanation that cannot be ruled out is the role of epitope 
specificity in pathogenesis. It is feasible that while the majority of the NC16A specific IgG4 
binds an epitope that enables it to function in an inhibitory manner, a small pool of the IgG4 
fraction may bind an epitope capable of inducing disease. Further studies are needed to 
explore this intriguing possibility.
In conclusion, our findings clearly show that anti-NC16A subclasses differ in their ability to 
induce disease upon passive transfer, and, moreover, that IgG4 anti-NC16A has a primary 
function of blocking the pathogenic effects of anti-NC16A IgG1,3 in vivo. These results 
highlight the potential role for IgG4 anti-NC16A blocking autoantibodies as a useful 
strategy for both the monitoring and treatment of BP. For example, it is possible that an 
increase in IgG4 anti-NC16A antibodies may serve as a biomarker for patients that are 
entering into long term remission. As such, the presence of IgG4 anti-NC16A antibodies 
may predict better outcomes upon reduction of immunosuppressive medications. On the 
other hand, administration of IgG4 anti-NC16A antibodies may represent a new treatment 
strategy in patients with suboptimal ratios of IgG1,3:1gG4 NC16A specific antibodies. 
These possibilities need to be more thoroughly explored, but highlight the translational 
aspect of our findings. More importantly, these findings may ultimately have implications 
for the monitoring and treatment of other autoantibody mediated diseases as well.
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HIGHLIGHTS
• Autoantibodies in bullous pemphigoid belong to the IgG1, IgG3, and 
IgG4 subclasses
• Patient derived antigen specific IgG1/3 induce disease in vivo
• Patient derived antigen specific IgG4 inhibits IgG1/3 induced disease in 
vivo
• Inhibitory IgG4 may be useful for treating bullous pemphigoid
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Figure 1. Levels of anti-NC16A IgG subclasses
NC16A-specific total IgG from three BP sera were purified using protein A/G column, 
followed by NC16A-specific affinity column. Levels of anti-NC16A IgG1, G2, G3, and G4 
were quantified by human IgG1-, G2-, G3- and G4-specific ELISA. IgG1, 3, and 4 are 
dominant IgG subclasses in 3 BP sera and IgG2 were below detection limit in BP2 and BP3. 
Data are expressed as mg IgG/ml serum.
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Figure 2. Anti-NC16A IgG induced dose-dependent BP disease in NC16A mice
Neonatal NC16A mice were injected i.d. with different amounts of anti-NC16A total IgG 
(100–300 μg/g body weight) and examined clinically for disease activity 24 hours post 
injection. A. Mice injected with 300 μg/g body weight (panels a, b) and 200 μg/g body 
weight (panels c, d) but not 100 μg/g body weight (panels e, f) developed clinical and 
histological subepidermal blister. D, dermis; E, epidermis; V, vesicle. Arrow, basal 
keratinocytes. B. Anti-NC16A IgG induced BP in a dose-dependent fashion. p<0.05, n=6 for 
each group.
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Figure 3. Anti-NC16A IgG4 inhibit binding and C
′ fixation of anti-NC16A IgG1,3 at the BMZ in vitro.
Skin sections of NC16A mice were incubated with anti-NC16A IgG1,3 (1 μg/ml), IgG4 
(0.25 μg/ml), or both IgG1,3 and IgG4 in the absence or presence of freshly prepared human 
serum (providing complete complement system). A. IgG binding. Anti-NC16A igG1,3, and 
4 stained the BMZ. Pre- or co-incubation of anti-NC16A IgG4 but not control IgG4 with 
anti-NC16A IgG1,3 drastically reduced binding of anti-NC16A IgG1,3 at the BMZ as 
detected by FITC-conjugated IgG1-spefici secondary antibody (panel d). B. C′ fixation. In 
the presence of human serum, anti-NC16A IgG1,3 and not IgG4 fixed complement as 
determined by C3 deposition at the BMZ using FITC-conjugated human C3-specific 
secondary antibody. Pre- or co-incubation of anti-NC16A IgG4 but not control IgG4 with 
anti-NC16A IgG1,3 significantly inhibited C′ fixation by anti-NC16A IgG1,3 (panel d).
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Figure 4. Anti-NC16A IgG4 inhibit BP in vivo
Neonatal NC16A mice were injected i.d. with BP1-derived anti-NC16A IgG1,3 (300 μg/g 
body weight) in the presence of normal human IgG4 control or anti-NC16A IgG4 (10:0 – 
10:5 ratio IgG1,3 vs. IgG4) and examined 24 h post injection. A. IgG passive transfer. Anti-
NC16A IgG1,3 bind to the BMZ (panels b, c), activate C′ as evidenced by C3 deposition at 
the BMZ (panel d) and induced BP blistering clinically (panel a) and histologically (panel 
e). In contrast, anti-NC16A IgG4 bind to the BMZ (panel g) and blocked anti-NC16A IgG1 
binding (panel h), C′ activation (panel i) and BP blistering (panel j). IgG1,3 vs. IgG4 ratio 
was 10:2.5. B. Inhibition of anti-NC16A IgG1,3-induced disease activity (clinical disease 
score), C′ activation (skin C5a levels) and neutrophil infiltration (skin tissue MPO 
enzymatic activity) by anti-NC16A IgG4 were dose dependent. The inhibition was 
expressed as % change. n=8.
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Figure 5. Anti-NC16A IgG4 inhibit BP in vivo
Neonatal NC16A mice were injected i.d. with anti-NC16A IgG1,3 (300 μg/g body weight) 
from BP1, BP2, and BP3 in the presence of normal human IgG4 control or anti-NC16A 
IgG4 from BP1 (10:5 ratio IgG1,3 vs. IgG4) and examined 24 h post injection. A. IgG 
passive transfer. Anti-NC16A IgG4 and not control IgG (panel a) abolished BP clinical 
blistering induced by anti-NC16A IgG1,3 (panels b–d). B. Anti-NC16A IgG4 and not 
control IgG significantly inhibited BP disease activity (disease score) induced by anti-
NC16A IgG1,3. C. Direct IF. Anti-NC16A IgG4 and not control IgG (panel a) blocked anti-
NC16A IgG1,3-induced C3 deposition at the BMZ (panels b–d). Anti-NC16A IgG4 and not 
control IgG also significantly inhibited activation (skin C5a level, D) and neutrophil 
infiltration (skin MPO activity, E) caused by anti-NC16A IgG1,3 from three BP patients. 
*p<0.05, n=8 for BP1, n=6 for BP2 and BP3.
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Figure 6. In vitro complement fixation of anti-NC16A IgG1,3 and IgG4
Antibody-sensitized sheep erythrocytes were incubated with complement, GST-NC16A 
fusion protein (0–100 μg/ml), anti-NC16A IgG1,3 or IgG4 (100 μg/ml) or both anti-NC16A 
IgG1,3 and IgG4. After 1 h incubation, lysis of sheep erythrocytes was quantified by reading 
OD540nm of the supernatant. Complement-fixing activity of anti-NC16A IgG was 
expressed as percent of inhibition of cell lysis. A. Complement fixation. Anti-NC16A 
IgG1,3 and not IgG4 fixed complement. B. Inhibition of C′ fixing activity of anti-NC16A 
IgG1,3 by IgG4. Anti-NC16A IgG4 inhibited C′ fixing activity of anti-NC16A IgG1,3 in a 
dose-dependent fashion. n=3, *p<0.05, **p<0.01, IgG1,3 vs. IgG4.
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Figure 7. Anti-NC16A IgG4 bind to FcγRs on neutrophils and induce BP in C5a reconstituted 
NC16A mice
Mouse neutrophils (1×106) were stained with anti-NC16A IgG1,3 or IgG4 from BP1. IgG 
bound neutrophils were quantified by flow cytometry using goat-anti-human IgG FITC 
conjugates. Anti-NC16A IgG1,3 and IgG4 exhibited comparable binding to FcγRs on 
mouse neutrophils (A) at 1–10 μg/ml concentrations (B). In vivo, anti-NC16A IgG4 induced 
BP blister in mC5a locally reconstituted NC16A mice (C). Clinical disease activity (D) and 
skin neutrophil infiltration (E) in the mC5a reconstituted NC16A mice were mC5a-
dependent. Similar results were seen using BP2 and BP3 anti-NC16A IgG1,3 and IgG4 (data 
not shown). n=6, p<0.01, mC5a vs. BSA groups.
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